Oscar J Pozo Selected Research

indolylacryloylglycine

7/2015

Mass spectrometric characterisation of a condensation product between porphobilinogen and indolyl-3-acryloylglycine in urine of patients with acute intermittent porphyria.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Oscar J Pozo Research Topics

Disease

5	Acute Intermittent Porphyria (Porphyria, Acute) 03/2022 - 04/2014
5	Neoplasms (Cancer) 01/2022 - 07/2014
3	Asthma (Bronchial Asthma) 02/2013 - 10/2011
2	Inflammation (Inflammations) 03/2022 - 04/2021
2	Mood Disorders (Mood Disorder) 02/2016 - 02/2016
2	Rhinitis 02/2013 - 08/2012
1	Insulin Resistance 01/2023
1	Frailty 01/2023
1	Fatty Liver 01/2023
1	Body Weight (Weight, Body) 11/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2022
1	Malaria 06/2022
1	COVID-19 03/2022
1	Pathologic Processes 01/2022
1	Vitamin B 6 Deficiency (Pyridoxine Deficiency) 01/2022
1	Myocardial Infarction 01/2022
1	ST Elevation Myocardial Infarction 01/2022
1	Diabetes Mellitus 01/2022
1	Dyslipidemias (Dyslipidemia) 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Ventricular Fibrillation 01/2022
1	Ischemia 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2021
1	Homocystinuria 01/2021
1	Metabolic Diseases (Metabolic Disease) 01/2021
1	Cocaine-Related Disorders (Cocaine Addiction) 01/2019
1	Smith-Lemli-Opitz Syndrome 01/2018
1	X-Linked Ichthyosis (Ichthyosis, X Linked) 01/2018
1	Chronic Pain 02/2016
1	Pain (Aches) 02/2016
1	Neuralgia (Stump Neuralgia) 02/2016
1	Hyperalgesia 02/2016
1	Neuroinflammatory Diseases 02/2016
1	Hypogonadism (Hypergonadotropic Hypogonadism) 08/2015
1	Porphyrias (Porphyria) 04/2014
1	Rare Diseases (Rare Disease) 04/2014
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 08/2012
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 11/2009

Drug/Important Bio-Agent (IBA)

3	Tryptophan (L-Tryptophan)FDA Link 03/2022 - 08/2017
3	Biomarkers (Surrogate Marker)IBA 03/2022 - 04/2014
3	Hydroxymethylbilane Synthase (Porphobilinogen Deaminase)IBA 01/2021 - 04/2014
3	Neurotransmitter Agents (Neurotransmitter)IBA 01/2019 - 02/2016
2	MelatoninIBA 01/2022 - 07/2014
2	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2022 - 05/2015
2	Hormones (Hormone)IBA 01/2022 - 05/2015
2	CeramidesIBA 10/2021 - 04/2021
2	EnzymesIBA 08/2017 - 04/2014
2	Heme (Haem)IBA 08/2017 - 04/2014
2	Budesonide (Pulmicort)FDA LinkGeneric 02/2013 - 08/2012
2	GlucocorticoidsIBA 02/2013 - 08/2012
1	harmolIBA 01/2023
1	Glucose (Dextrose)FDA LinkGeneric 01/2023
1	CorticosteroneIBA 11/2022
1	Antimalarials (Antimalarial Agents)IBA 06/2022
1	artemisinin (artemisinine)IBA 06/2022
1	hydroxymethylbilaneIBA 03/2022
1	KynurenineIBA 03/2022
1	Methamphetamine (Desoxyn)FDA LinkGeneric 01/2022
1	Carboxylic AcidsIBA 01/2022
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022
1	Linoleic Acid (Linoleate)IBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	OilsIBA 01/2022
1	4-hydroxyphenylethanolIBA 10/2021
1	SphingolipidsIBA 10/2021
1	LipidsIBA 10/2021
1	Adenine NucleotidesIBA 04/2021
1	Niacinamide (Nicotinamide)FDA LinkGeneric 04/2021
1	NAD (NADH)IBA 04/2021
1	ParaffinIBA 02/2021
1	Formaldehyde (Formol)FDA Link 02/2021
1	heme arginateIBA 01/2021
1	HomocysteineIBA 01/2021
1	givosiranIBA 01/2021
1	Methionine (L-Methionine)FDA Link 01/2021
1	Synthetic CathinoneIBA 01/2019
1	Oxidoreductases (Dehydrogenase)IBA 01/2018
1	SolventsIBA 01/2018
1	Estriol (Epiestriol)IBA 01/2018
1	Serotonin (5 Hydroxytryptamine)IBA 02/2016
1	CytokinesIBA 02/2016
1	Ethanol (Ethyl Alcohol)IBA 02/2016
1	Glutamic Acid (Glutamate)FDA Link 02/2016
1	salicylhydroxamic acid (SHAM)IBA 02/2016
1	PorphobilinogenIBA 07/2015
1	indolylacryloylglycineIBA 07/2015
1	SteroidsIBA 04/2014
1	Salmeterol Xinafoate (Serevent)FDA Link 10/2011
1	Plasminogen Activators (Plasminogen Activator)IBA 11/2009
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 11/2009

Therapy/Procedure

1	Aftercare (After-Treatment) 01/2023
1	Therapeutics 06/2022
1	Adrenalectomy 08/2015